Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, FDA pathway risks, and royalty-sharing details make Orchestra BioMed’s disclosures anything but light reading. If you have ever searched a 300-page 10-K for the next payment trigger with Medtronic or wondered when executives last sold shares ahead of pivotal data, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn dense text into plain English, so understanding Orchestra BioMed SEC documents with AI becomes practical. Whether you need an Orchestra BioMed quarterly earnings report 10-Q filing, an Orchestra BioMed 8-K material events explained, or the latest Orchestra BioMed insider trading Form 4 transactions, everything appears in one feed—updated in real time as soon as EDGAR posts.
What can you uncover?
- Milestone revenue figures from partnership footnotes in the Orchestra BioMed annual report 10-K simplified
- Trial cost run-rates and cash burn trends in each Orchestra BioMed earnings report filing analysis
- Orchestra BioMed executive stock transactions Form 4 that flag buying or selling before catalyst events
- Board pay packages within the Orchestra BioMed proxy statement executive compensation
- Device safety updates filed as “Item 8.01” within an 8-K
Every document—10-K, 10-Q, 8-K, S-1, or Orchestra BioMed Form 4 insider transactions real-time—is automatically indexed, summarized, and linked to the original PDF. Save hours poring over medical-device jargon and focus on decisions instead. Complex filings, clarified.
Orchestra BioMed Holdings, Inc. reported a net loss of $19.4 million for the three months ended June 30, 2025 and $38.1 million year-to-date, compared with $16.0 million and $29.4 million in the prior-year periods. Total revenue remained modest at $0.836 million for the quarter, driven by partnership and product sales, while research and development expense rose to $13.9 million in the quarter as the company advances multiple clinical programs.
On the balance sheet, cash and cash equivalents totaled $18.7 million and marketable securities $15.2 million, giving total assets of $42.8 million versus $76.2 million at year-end 2024. Stockholders' equity declined to $0.3 million. Operating cash used was $32.1 million for the six months ended June 30, 2025. Deferred revenue from the Terumo collaboration was $14.0 million, with approximately $4.5 million expected to be recognized in the next 12 months. Management states available capital (including subsequent proceeds) is sufficient to fund operations through at least one year from issuance.
Orchestra BioMed Holdings, Inc. reported an award of 80,000 restricted stock units (RSUs) to reporting person Taylor Andrew Lawrence, identified as Chief Financial Officer, with an earliest transaction date of 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition was recorded at a price of $0 per RSU.
The RSUs vest in three tranches subject to the reporting person’s continuous service: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months after the grant date. After the award the reporting person beneficially owns 480,788 shares, reported as direct ownership. The Form 4 is signed by Andrew Taylor on 08/08/2025.
Aryeh Jason, a director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock, and the filing shows the reporting person beneficially owns 107,482 shares following the award.
The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date. The transaction is reported as a non-derivative equity award (Transaction Code A) with a reported price of $0 and is held in a direct ownership form.
Insider grant and holdings update: Darren Sherman, listed as a director and as President and Chief Operating Officer of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 120,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the award was reported as acquired at a $0 price.
The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continued service. Following the reported transaction, the filing shows 923,837 shares beneficially owned by the reporting person in a direct ownership form.
Orchestra BioMed Holdings (OBIO) director Pamela Ann Connealy was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition is recorded at a $0 price.
The RSUs are scheduled to vest on the one‑year anniversary of the grant date, subject to the reporting persons continuous service through that date. Following the award, Ms. Connealy beneficially owns 48,711 shares of common stock, held directly.
The filing lists Ms. Connealys relationship to the issuer as a director. No derivative securities or dispositions are reported in this Form 4.
Orchestra BioMed Holdings director Mack John Prosper was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a per-unit price of $0. The RSUs are scheduled to vest on the one-year anniversary of the grant, subject to the reporting persons continuous service through that date. After this award the reporting person beneficially owns 40,286 shares on a direct basis.
The Form 4 shows the transaction as an acquisition (code A) and was filed by one reporting person. No derivative securities or additional transactions are reported in this filing and no other material details are provided.
Orchestra BioMed director Eric S. Fain was awarded 7,500 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a transaction price of $0. The RSUs will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date.
The Form 4 reports that following the reported acquisition the Reporting Person beneficially owns 7,500 shares directly and 58,449 shares indirectly through the Fain Living Trust. The filing discloses the RSU grant as the non-derivative acquisition reported on the form.
Orchestra BioMed Holdings, Inc. (OBIO) filed a Form 4 reporting that director Chris Cleary was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the grant is recorded with a price of $0 in the filing. The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the reporting persons continuous service through that date.
The transaction is shown as an acquisition and, after the award, Mr. Cleary beneficially owns 37,577 shares on a direct basis. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on 08/08/2025.
Orchestra BioMed Holdings reported that Director and CEO David P. Hochman was awarded 100,000 restricted stock units (RSUs) on 08/07/2025, each representing a contingent right to one share of common stock. After the award, Mr. Hochman's reported direct beneficial ownership is 645,460 shares; indirect holdings include 449,331 shares held by the DPH 2008 Trust and smaller trust holdings of 2,000, 2,000, 2,000 and 3,140 shares. The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continuous service. The filing identifies Mr. Hochman as Chief Executive Officer and Chairperson.
Orchestra BioMed director David Pacitti was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the RSUs vest on the one-year anniversary of the grant, subject to the reporting person's continuous service through that date.
Following the award, the reporting person beneficially owns 44,968 shares of common stock in a direct ownership form. The RSUs carry no stated cash price and will convert to shares upon vesting.
FAQ
What is the current stock price of Orchestra BioMed Holdings (OBIO)?
What is the market cap of Orchestra BioMed Holdings (OBIO)?
